ChromaDex Corporation (CDXC)
CDXC Price and Sentiment
CDXC Latest news
ChromaDex Corporation (CDXC) CEO Rob Fried on Q3 2021 Results - Earnings Call Transcript
ChromaDex (CDXC) delivered earnings and revenue surprises of -30.00% and 0.76%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex (NASDAQ:CDXC) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:02 PM. Here's what investors need to know about the announcement.
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2021. Third Quarter 2021 and Recent Highlights Total net sales were $17.3 million, up 22% from the prior year quarter. Tru Niagen® net sales were $14.8 million, a 24% increase from the prior year quarter. Gross margin was 61.1%, a 150 basis point increase from the prior year quarter. Net loss was $(8.9) million or $(0.13) per share, a decline of $0.06 per share from the prior y
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)2021-10-18 06:34
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ataxia--ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders, conducted by Michèl A.A.P. Willemsen MD, PhD of Radboud University Medical Center. The study investigated ChromaDex's proprietary Niagen® ingredient (patented nicotinamide riboside, or “NR”) in patients with ataxia-telangiectasia (AT), a rare, inherited neurodegenerative disorder characterized by premat
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wednesday, Nov. 3, 2021 at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sep. 30, 2021. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the third quarter results
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #cdxc--ChromaDex Corp. (NASDAQ:CDXC) today announced that a jury in the United States District Court for the Central District of California found that Elysium Health, Inc. (“Elysium”) breached its contract with ChromaDex by failing to pay for product it ordered and received in 2016. Based on the jury's verdict, Elysium and Mark Morris will be required to pay ChromaDex approximately $2.25 to $2.50 million in damages and estimated interest. “It took nearly five years and ha
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChinaCrossBorder--ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (“Sinopharm Xingsha”) to conduct cross-border sales of Tru Niagen® in mainland China. Sinopharm Xingsha is a subsidiary of Sinopharm Group, with businesses including pharmaceutical manufacturing, marketing and distribution of drugs, and food supplements and healthcare products. It is the main platform of Sinopharm Group for food supplements and hea
ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)2021-09-20 06:33
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #nicotinamideriboside--ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen® (patented nicotinamide riboside, or “NR”) in various health outcomes. Through the industry-leading ChromaDex External Research Program (CERP™), ChromaDex supplies Niagen® to researchers around the world at no cost to help advance the understanding of NR's impact on various age-related health cond